Asthma

Refractory (planetary science)

Dupilumab

Bullous pemphigoid

Atopic dermatitis

Benralizumab

Omalizumab

Dermatology

Pemphigoid

Immunoglobulin E

Immunology

Eosinophil

Physics

Monoclonal antibody

Mepolizumab

Astrobiology

Monoclonal

Medicine

Antibody

Frontiers in Immunology

Bullous pemphigoid (BP) is a blistering autoimmune skin disease. Omalizumab, a monoclonal antibody directed to IgE, showed a beneficial effect in treatment of recalcitrant BP in case series. More recently, dupilumab, an interleukin (IL)-4-receptor alpha antagonist, also showed promising preliminary results. We describe a patient with refractory BP who showed a complete response to a combination therapy with omalizumab and dupilumab.

Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid